SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Georgia O'Keeffe

PatientGeorgia O'Keeffe
Date of birth1945-11-15
IdentifiersMRN HR-ET011-SYN; SSN (made up) 000-11-5873
Document date2026-07-02
AuthorWendell Ashby, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Treat-and-extend retina visit and primary care review of vision rehabilitation. [S]

History of Present Illness

Ms. O'Keeffe returns eight weeks after her third injection, the first extended interval. Her left-eye vision has held, with no new distortion, and daily Amsler checks of each eye show no change. Low-vision rehabilitation is complete: task lighting and a stand magnifier are set up in the studio, and high-contrast labels mark her paints and household controls. She is painting daily. The driving assessment cleared her for short local routes by day. She takes the AREDS2 supplement daily and has had no falls. [S]

ElementDetail
Interval changeLeft-eye vision stable over eight weeks; no new distortion
Amsler gridDaily checks of each eye; no change
Low-vision rehabilitationTask lighting, stand magnifier, and high-contrast labels in place
DrivingCleared for short local routes by day
FunctionPainting daily; independent at home; no falls

Review of Systems

SystemResultFinding
EyesNegativeNo new distortion, blur, pain, flashes, or floaters
ConstitutionalNegativeWeight stable; good energy
MusculoskeletalNegativeNo falls
PsychiatricNegativeMood good; PHQ-2 score 0

4 systems reviewed. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-02Body height165cmS
2026-07-02Body weight56.5kgS
2026-07-02Body mass index (BMI) [Ratio]20.8kg/m2S
2026-07-02Systolic blood pressure128mm[Hg]S
2026-07-02Diastolic blood pressure72mm[Hg]S
2026-07-02Heart rate70/minS
2026-07-02Respiratory rate14/minS
2026-07-02Body temperature36.7CelS
2026-07-02Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-02Visual acuity best corrected Right eye by ETDRS eye chart77{letters}>=80LowS
2026-07-02Visual acuity best corrected Left eye by ETDRS eye chart70{letters}>=80LowS
2026-07-02Macular grid.center subfield thickness by OCT268um200-300 umNormalS
2026-07-02Right eye Intraocular pressure15mm[Hg]10-21 mmHgNormalS
2026-07-02Left eye Intraocular pressure15mm[Hg]10-21 mmHgNormalS
2026-07-02Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 2026-07-02; see the Vital Signs section. [S]

SystemFinding
GeneralWell, energetic
Visual acuityBest-corrected 77 letters right and 70 letters left
Intraocular pressure15 mmHg in each eye before injection
Anterior segmentQuiet in both eyes
Dilated fundus, left eyeNo fluid or hemorrhage
Dilated fundus, right eyeLarge drusen unchanged; no fluid or hemorrhage
OCT, both eyesLeft eye dry, central subfield thickness 268 µm. Right eye large drusen without fluid
After injection, left eyeOptic nerve head perfused; counts fingers; no pain

Problems

ProblemClinical statusVerificationCodeProvenance
Neovascular (wet) age-related macular degeneration, left eye, with active choroidal neovascularizationactiveconfirmed H35.3221S — Synthetic modern diagnosis linked to her documented failing eyesight; the historical type of macular degeneration is not recorded.
Nonexudative age-related macular degeneration, right eye, intermediate stageactiveconfirmed H35.3112S — Synthetic finding in the fellow eye.
New distortion (wavy lines) and a blurred central spot with reduced acuity in the left eye; suspected neovascular macular degeneration, urgent retina referralresolvedconfirmed H53.15S — Synthetic presenting concern at the index visit, superseded by the OCT diagnosis at the retina consultation; her failing eyesight is documented (D).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBest-corrected visual acuity (ETDRS letters)Every injection visitCompleted today77 letters right and 70 letters left
ImagingOptical coherence tomography of the maculaEvery injection visitCompleted todayBoth eyes. Left dry at 268 µm; right drusen without fluid
ExaminationIntraocular pressure before and after injectionEvery injection visitCompleted todayBefore injection 15 mmHg in each eye; after injection, optic nerve perfused and counting fingers
ExaminationDilated examination of the fellow (right) eyeEvery injection visitCompleted todayLarge drusen unchanged; no fluid on OCT
ExaminationComprehensive dilated eye examinationEvery 1 to 2 years at 65 or olderUp to dateBoth eyes examined in full at the March retina consultation and again today
Medication safetyIntravitreal injection safetyEvery injection visitCompleted todayFourth injection; no complication to date
Self-managementTeaching on warning signs of endophthalmitis and retinal detachmentEvery injection visitCompleted todayReviewed again before the ten-week interval
Self-managementDaily home Amsler grid, each eyeDailyCompleted todayDaily checks recorded; no change in either eye
Medication safetyAREDS2 supplement for intermediate AMDDaily, long termCompleted todayTaking it daily
ReferralLow-vision rehabilitation, with home fall-risk review and a driving assessmentOnce central vision is reduced; review as vision changesUp to dateCompleted since the last visit: lighting, magnifier, and labels in place; cleared for short local daytime driving. Review if vision changes
SurveyFunctional vision assessment (reading, color, driving, work)At diagnosis; again with changeCompleted todayPainting daily with aids; reading with the magnifier; daytime local driving only
SurveyDepression screen (PHQ-2)At follow-up, because vision loss raises the risk of depression; periodically at 65 or olderCompleted todayScore 0, down from 1 at intake
SurveyCognitive screen (Mini-Cog)Annually at 65 or olderUp to date5 of 5 at intake in March; next at the annual wellness visit

Goal progress:

Guideline basis: Age-Related Macular Degeneration Preferred Practice Pattern (2024); CMID: Clinical Monitoring Intelligence Database, cataract and glaucoma monographs (eye-examination items) (2026)

Follow-up: Retina visit in ten weeks for acuity, OCT, pressure, and the fifth injection. Annual wellness visit in the fall. Next scheduled visit 2026-10-15: subsequent annual wellness visit. [S]